Author(s): Lohit Kumar Kalita1, Chayanika Kalita2, Syeda Mohsina Rohman3, Pabitra Kumar Gogoi4, Umesh Ch. Sarma5
Aspartate Amino Transferase (AST) is normally present in red blood cells, liver, heart, muscle tissue, pancreas and kidneys. So, the amount of AST in the blood is directly related to the extent of the tissue damage. Lactate Dehydrogenase (LDH) is an enzyme that transfer a hydride from one molecule to another. Lactate dehydrogenase is of medical significance because it is found extensively in body tissue, such as blood cells and heart muscle. Bortezomib has recommended as novel approach to the treatment of multiple myeloma producing rapid control.
AIM: The aim of this study was to investigate the relationship of serum Aspartate Amino Transferase (AST) and Lactate Dehydrogenase (LDH) level with prognosis of multiple myeloma treated with bortezomib-dexamethasone regimen.
MATERIAL AND METHODS: We conducted a retrospective study of 30 newly diagnosed cases multiple myeloma treated with bortezomib (1.3 mg/m2 on days 1, 4, 8, and 11 of a 21-day cycle) and dexamethasone 40 mg once in a week.
RESULTS: We observed high levels of AST and LDH during the treatment period in maximum number of patients of multiple myeloma with ISS stage II & III. The present study suggests that the possibility that the prognosis of patients with high levels of AST and LDH might be worse.
CONCLUSION: From the study we observed an association between worse prognosis of multiple myeloma treated with Bortezomib-dexamethasone regimen and corresponding high level of serum LDH and AST during the treatment period.